

534,528

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



Rec'd PCT/PTO 11 MAY 2005




(43) International Publication Date  
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number  
WO 2004/043971 A1

- (51) International Patent Classification<sup>7</sup>: C07F 9/30
- (21) International Application Number: PCT/CH2003/000750
- (22) International Filing Date: 14 November 2003 (14.11.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0226550.2 14 November 2002 (14.11.2002) GB
- (71) Applicant (for all designated States except US): GIVAUDAN SA [CH/CH]; Chemin de la Parfumerie 5, CH-1214 Vernier (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SCHRÖDER, Fridtjof [DE/CH]; Im Grund 14, CH-8442 Hettlingen (CH). NATSCH, Andreas [CH/CH]; Kleindorfstrasse 44, CH-8707 Uetikon (CH).
- (74) Agent: McSTEA, John, Anthony; Givaudan Schweiz AG, Global Patents, Überlandstrasse 138, CH-8600 Dübendorf (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHOSPHINIC ACID ANALOGS OF GLUTAMATE



(57) Abstract: Inhibitors of axillary malodour having the formula (I): wherein R has the same meaning as given in the specification.

WO 2004/043971 A1

PHOSPHINIC ACID ANALOGS OF GLUTAMATE

This invention is concerned with compounds useful for the prevention or suppression of human malodour, in particular human axillary malodour.

It is known that fresh sweat is odourless and that odour is only formed upon contact of sweat with skin bacteria (for example bacteria of the genera of *Staphylococcus* and *Corynebacteria*) and it is believed that odourless molecules present in sweat are degraded by bacteria colonising the axilla. It is generally accepted (Labows *et. al.*, Cosmet. Sci Technol. Ser. (1999), 20:59-82) that highly unpleasant malodour is released from fresh sweat mainly by the *Corynebacteria* genus of bacteria. The principal constituents thought to be responsible for malodour include volatile steroids, volatile sulphur compounds and short-chain, branched fatty acids.


It has been suggested to treat malodour by eradicating the bacteria responsible for causing the odour. Indeed, commercially available cosmetic deodorants often contain antibacterial compounds that generally inhibit the growth of skin microflora.

Antibacterial compounds currently used in deodorant products include, for example Triclosan (2,4,4'-trichloro-2'-hydroxy-diphenyl-ether). However, a draw-back to the use of antibacterials is the potential for disturbing the equilibrium of the skin's natural microflora.

Fatty acids, in particular short chain, branched fatty acids are known to play a role in axillary malodour, and are particularly foul smelling components of stale sweat. In co-pending application PCT/CH02/00262 the applicant has disclosed an enzyme that mediates in a process of transforming odourless compounds found in sweat into these malodorous fatty acids. In this co-pending application there is also disclosed a broad class of compounds having activity as inhibitors of the enzyme.

Nevertheless there remains the need to find further compounds displaying good inhibitory properties with respect to the above mentioned enzyme.

Accordingly, the invention provided in a first aspect a compound of formula (I)



wherein R is a substituted alkyl, benzyl or allyl residue selected from the group consisting of

- a) nonyl;
- b) 4,4,4-trifluoro-propyl;
- c) 2-methyl-4-phenyl-butyl;
- d) 4-trifluoromethyl-phenyl;
- e) pentafluorophenyl;
- f) 4-fluoro-phenyl;
- g) naphthalene-2-yl;
- h) biphenyl-2-yl;
- i) 5,5,7,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalene-2-yl;
- k) 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl;
- l) 1,1,3,3-tetramethyl-indan-5-yl;
- m) styryl;
- n) 2,6-dimethyl-heptyl;
- o) 2-(4-tert-Butyl-phenyl)-1-methyl-vinyl;
- p) 2-(4-Isopropyl-phenyl)-1-methyl-vinyl;
- q) 1-(1,7,7-Trimethyl-bicyclo[2.2.1]hept-2-yl)-ethyl;
- r) 2-(4-Isobutyl-phenyl)-1-methyl-vinyl;
- s) 2-(2-isopropyl-phenyl)-1-methyl-ethenyl;
- t) 2-phenyl-ethyl;
- u) cyclohexyl-methyl;
- v) 2,2-dimethyl-propyl;
- w) 2-(pentafluorophenyl)-ethyl;
- x) 3-phenyl-propyl;
- y) heptyl;
- z) 4-isopropyl-cyclohex-1-enyl;
- za) decyl;

- zb) hexyl;
- zc) trans-4-isopropyl-cyclohexyl;
- zd) 5-ethyl-2-methyl-heptyl;
- ze) 2,6,10-trimethyl-undecyl;
- zf) 1-methyl-3-(2,2,3-trimethyl-cyclopentyl)-propyl; and
- zg) octyl.

Compounds of the formula (I) contain chiral atoms and as such they can exist as isomeric mixtures or they may exist as pure stereoisomers. Most preferred are compounds have an S-configuration on the carbon atom in the position alpha to the carboxyl group.

As stated hereinabove, compounds of the present invention may interact with an enzyme thereby to reduce the enzyme's ability to cleave compounds in sweat leading to release of malodorous acids from odourless fresh sweat. That enzyme, described in the afore-mentioned co-pending application, was isolated from the bacteria of the genus *Corynebacteria* that can be found colonising the axilla, in particular certain *Corynebacteria sp.*, more particularly *Corynebacterium striatum* Ax 20 which has been submitted on the 26, April 2001 to the International Depository Authority DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, D-38124 Braunschweig. The Accession Number provided by the International Depository Authority is DSM 14267. The enzyme was found to occur intracellularly and can be released from the cells by mechanical disruption of the cell envelope. Thus, it may be isolated from cellular extracts obtained from wild-type bacterial strains, especially from strains of *Corynebacteria* isolated from the human axilla, in particular *Corynebacterium striatum* Ax 20. In the alternative, it may be produced by recombinant means which are well known to persons skilled in the art.

The amino acid sequence of this enzyme is set forth in SEQ ID No. 1 and a nucleic acid sequence encoding for this enzyme is set forth in SEQ ID No. 2, both of which sequences are shown below.

Compounds of the present invention display inhibition of the enzyme at concentrations of about 1 to 500, nanomolar more particularly from 5 nanomolar to 500 nanomolar concentration in vitro, e.g. from 9 to 150 nanomolar. Furthermore, having regard to the lipophilicity of the residue R, the compounds are adapted to penetrate the cell walls of the enzyme-producing bacteria, as such, they are efficacious in vivo.

Indeed, the nature of the residue R appears to influence the ability of compounds to penetrate the cellular walls of different bacteria colonising the axilla and which are implicated in malodour production. For example, other strains of *Corynebacteria*, for example *Corynebacterium bovis* and *Corynebacterium jeikeium*, or bacteria of the genus *Staphylococci* found in the microflora of the axilla also produce related enzymes that themselves mediate in biochemical reactions wherein L-glutamine derivatives are cleaved at N $\alpha$ . The compounds of the present invention may interfere in cellular processes of a wide variety of bacterial strains thereby resulting in the suppression or prevention of malodour from these sources.

The in vitro activity of the compounds as inhibitors may be measured in terms of either their  $IC_{50}$  values or their  $K_i$  values, both of which measures are well known to the person skilled in the art. As is well known, the  $IC_{50}$  value provides the concentration of an inhibitor needed to reduce enzyme velocity by half at a given substrate concentration. This value is dependent on the affinity of the substrate for the enzyme which is reflected in the value  $K_m$  of the substrate. In this way, the  $K_i$  value may be determined for a given substrate and a given substrate concentration by measuring  $IC_{50}$  and then calculating according to the following formula

$$K_i = \frac{IC_{50}}{1 + \frac{[Substrate]}{K_m}}$$

The uptake of the compounds in bacterial cells and the inhibition of the enzyme contained therein may be measured using an assay based on stationary-phase living cells. Thus, cells may be incubated along with inhibitory compound or compounds, and

the substrate (i.e. the material found in sweat, which when cleaved by the enzyme forms the malodorous acids), and the release of acids may be measured at various inhibitor concentrations. By comparing  $IC_{50}$  values obtained with the living cells with the  $IC_{50}$  values obtained with the isolated enzyme, the ease of penetration of the compounds into the bacterial cells can be assessed.

Compounds of the present invention may be added to any cosmetic and personal care products such as sticks, roll-ons, pump-sprays, aerosols, deodorant soaps, powders, solutions, gels, creams, sticks, balms and lotions to enhance the deodorising effect of these products. Preferably, a compound of the present invention may be employed in said products in amounts of about 0.01 to 0.5% by weight.

The above-mentioned products, in addition to the inhibitors, may comprise anti-bacterial agents known in the art, e.g. Triclosan. The products may also comprise dermatologically acceptable ingredients such as are commonly used in these types of product. Examples of such additional ingredients include fragrances, colorants, opacifiers, buffers, antioxidants, vitamins, emulsifiers, UV absorbers, silicones and the like. As is also well known, all products can be buffered to the desired pH.

In addition to the inhibitor, a deodorant cologne may comprise ethanol and fragrance. Fragrance may be present from 1 to 10% and the ethanol can be present to make up the mass to 100%.

Additional ingredients in a typical ethanol-free deodorant stick may include polyols, such as propylene glycol; derivatives thereof, such as propylene-glycol-3-myristyl ether (Witconol APM); water; a surfactant such as sodium stearate; and fragrance. The polyol may be present in an amount of 30 to 40%; the derivatives of the polyol likewise may be present at about 30 to 40%; water may be present to about 10 to 20%; the surfactant may be present to 5 to 10%; and the fragrance may be present in an amount up to 10%.

A typical antiperspirant stick might contain as additional ingredients such as Ethylene Glycol Monostearate (e.g. from 5 to 10%); Shea butter (e.g. from 3 to 5%); Neobee

1053 (PVO International) (e.g. from about 12 to 15%); Generol 122 (Henkel) (e.g. from about 3 to 7%); Dimethicone (DC 345)(e.g. from 30 to 40%); aluminium sesquichlorohydrate (e.g. from about 15 to 20%); and a fragrance, e.g. from 1 to 10%.

An antiperspirant aerosol may contain ethanol, e.g. from about 10 to 15%; zirconium aluminium tetrachlorohydrate, e.g. from about 3 to 5%; Bentone 38, e.g. from about 1 to 2%; fragrance in an amount aforementioned; and a hydrocarbon propellant, e.g. S-31, up to 100% based on the total aerosol composition.


An antiperspirant pump composition may contain aluminium sesquichlorohydrate, e.g. from 15 to 25%; water, e.g. from 50 to 60%; Triton X-102 (Union carbide), e.g. from 1 to 3%; dimethyl Isosorbide (ICI), e.g. from 15 to 25 %; and a fragrance in an amount as aforementioned.

All percentages mentioned above are in wt %.

Accordingly, the present invention relates to the use of the compounds of formula (I) and/or compositions containing same for the elimination or suppression of malodour. The invention also relates to compositions comprising an odour-suppressing quantity of an inhibitor compound, which acts as an inhibitor of the enzyme, and dermatologically acceptable vehicles that are generally well known in the art of cosmetic and personal care products.

The invention also provides in another of its aspects, a method of suppressing axillary malodour comprising the step of providing a composition for application to the skin of a person in need of treatment, said composition containing an inhibitor compound and dermatologically acceptable vehicle therefor, said compound being selected from one or more compounds of formula (I) described above.

A compound of formula (I) may be prepared according to synthetic protocols as set out in detail below with reference to Scheme 1, Scheme 2 and the Examples




- A) 5 equivalents (eq.)  $\text{HP}(\text{OTMS})_2$  for 2 h at  $130^\circ\text{C}$ .
- B) 1 eq benzylic or allylic bromide (6 or 8), 3 eq BSA, at  $25^\circ\text{C}$ . The product (4) is obtained in quantitative yield.
- C) 1 eq alkylphosphonic acid (3), 5 eq HMDS for 3 h at  $130^\circ\text{C}$ , then 1 eq acrylate (1) for 4 h at  $130^\circ\text{C}$ , then EtOH at  $70^\circ\text{C}$ . The product (4) is obtained in quantitative yield.
- D) 10-20 weight-% Pt/C, 1 atm  $\text{H}_2$ , AcOEt / EtOH 2:1,  $25^\circ\text{C}$ . Or Raney-Ni, EtOH,  $25^\circ\text{C}$ , 1 atm  $\text{H}_2$ .
- E) 1 N LiOH / EtOH for 1 day at  $25^\circ\text{C}$  to give the product in quantitative yield.
- F) 2.2 eq  $(\text{iPr})_3\text{SiH}$  in TFA at  $25^\circ\text{C}$  for 3 h to provide compounds of the present invention.

The acrylate starting material (1) may be formed according to a method described in co-pending application PCT/CH02/00262.

The alkyl, benzyl or allyl halides (7,6,8) are either commercially available or may be formed from commonly available starting materials according to synthetic protocols known per se and set out in Scheme 2 below.





Scheme 2

G) 1 eq Br<sub>2</sub> at 170°C for 4 h.

H) 2 eq Pyridine, 1.2 eq PPh<sub>3</sub>, 1.2 eq Iodine at 0°C for 2 h.

I) 0.35 eq NaBH<sub>4</sub>, MeOH for 2 h at 0°C, to provide the allylic alcohols in quantitative yield.

J) Et<sub>2</sub>O, 0.4 eq PBr<sub>3</sub> for 5 h at 0°C to provide the allylic bromides in quantitative yields.

K) 3-5 eq HP(OTMS)<sub>2</sub> in CH<sub>2</sub>Cl<sub>2</sub>, for 16 h.

L) 2 eq NaH<sub>2</sub>PO<sub>2</sub>(H<sub>2</sub>O), 1 eq BEt<sub>3</sub>, MeOH for 6 h at 25°C.

There now follows a series of Examples that serve to illustrate the invention.

### Examples

The following compounds are formed according to the following syntheses:

- 5a** 4-Carbamoyl-2-(decyl-hydroxy-phosphinoylmethyl)-butyric acid
- 5b** 4-Carbamoyl-2-[hydroxy-(4,4,4-trifluoro-butyl)-phosphinoylmethyl]-butyric acid
- 5c** 4-Carbamoyl-2-[hydroxy-(3-methyl-5-phenyl-pentyl)-phosphinoylmethyl]-butyric acid
- 5d** 4-Carbamoyl-2-[hydroxy-(4-trifluoromethyl-benzyl)-phosphinoylmethyl]-butyric acid
- 5e** 4-Carbamoyl-2-(hydroxy-pentafluorophenylmethyl-phosphinoylmethyl)-butyric acid
- 5f** 4-Carbamoyl-2-[(4-fluoro-benzyl)-hydroxy-phosphinoylmethyl]-butyric acid

- 5g** 4-Carbamoyl-2-(hydroxy-naphthalen-2-ylmethyl-phosphinoylmethyl)-butyric acid
- 5h** 2-(Biphenyl-2-ylmethyl-hydroxy-phosphinoylmethyl)-4-carbamoyl-butyric acid
- 5i** 4-Carbamoyl-2-[hydroxy-(5,5,7,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-phosphinoylmethyl]-butyric acid
- 5k** 4-Carbamoyl-2-[hydroxy-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-phosphinoylmethyl]-butyric acid
- 5l** 4-Carbamoyl-2-[hydroxy-(1,1,3,3-tetramethyl-indan-5-ylmethyl)-phosphinoylmethyl]-butyric acid
- 5m** E-4-Carbamoyl-2-[hydroxy-(3-phenyl-allyl)-phosphinoylmethyl]-butyric acid
- 5n** 4-Carbamoyl-2-[(3,7-dimethyl-octyl)-hydroxy-phosphinoylmethyl]-butyric acid
- 5o** E-2-[[3-(4-tert-Butyl-phenyl)-2-methyl-allyl]-hydroxy-phosphinoylmethyl]-4-carbamoyl-butyric acid
- 5p** E-4-Carbamoyl-2-{hydroxy-[3-(4-isopropyl-phenyl)-2-methyl-allyl]-phosphinoylmethyl}-butyric acid
- 5q** 4-Carbamoyl-2-{hydroxy-[2-(1,7,7-trimethyl-bicyclo[2.2.1]hept-2-yl)-propyl]-phosphinoylmethyl}-butyric acid
- 5r** E-4-Carbamoyl-2-{hydroxy-[3-(4-isobutyl-phenyl)-2-methyl-allyl]-phosphinoylmethyl}-butyric acid
- 5s** E-4-Carbamoyl-2-{hydroxy-[3-(2-isopropyl-phenyl)-2-methyl-allyl]-phosphinoylmethyl}-butyric acid
- 5t** 4-Carbamoyl-2-[hydroxy-(3-phenyl-propyl)-phosphinoylmethyl]-butyric acid
- 5u** 4-Carbamoyl-2-[(2-cyclohexyl-ethyl)-hydroxy-phosphinoylmethyl]-butyric acid
- 5v** 4-Carbamoyl-2-[(3,3-dimethyl-butyl)-hydroxy-phosphinoylmethyl]-butyric acid
- 5w** 4-Carbamoyl-2-[hydroxy-(2-pentafluorophenyl-ethyl)-phosphinoylmethyl]-butyric acid
- 5x** 4-Carbamoyl-2-[hydroxy-(4-phenyl-butyl)-phosphinoylmethyl]-butyric acid
- 5y** 4-Carbamoyl-2-(hydroxy-octyl-phosphinoylmethyl)-butyric acid
- 5z** 4-Carbamoyl-2-[hydroxy-(4-isopropyl-cyclohex-1-enylmethyl)-phosphinoylmethyl]-butyric acid
- 5za** 4-Carbamoyl-2-(hydroxy-undecyl-phosphinoylmethyl)-butyric acid
- 5zb** 4-Carbamoyl-2-(heptyl-hydroxy-phosphinoylmethyl)-butyric acid

**5zc** 4-Carbamoyl-2-[hydroxy-(4-isopropyl-cyclohexylmethyl)-phosphinoylmethyl]-butyric acid













**5zd** 4-Carbamoyl-2-[(6-ethyl-3-methyl-octyl)-hydroxy-phosphinoylmethyl]-butyric acid

**5ze** 4-Carbamoyl-2-[hydroxy-(3,7,11-trimethyl-dodecyl)-phosphinoylmethyl]-butyric acid


**5zf** 4-Carbamoyl-2-{[hydroxy-[2-methyl-4-(2,2,3-trimethyl-cyclopentyl)-butyl]-phosphinoylmethyl]-butyric acid

**5zg** 4-Carbamoyl-2-(hydroxyl-nonyl-phosphinoylmethyl)-butyric acid.


Structures of these compounds are set out below:



11



12



The following Examples are described with reference to Scheme 1 and Scheme 2. All compounds referred to in the Examples are defined by the combination of the corresponding compound number given in Scheme 1 or Scheme 2 and the letter code of the corresponding "R" residue. For example (4l) stands for compound 4 of Scheme 1, wherein R is 1,1,3,3-tetramethyl-indan-5-yl.

#### Example 1:

##### A) Preparation of 2-Hydroxyphosphinoylmethyl-4-(trityl-carbamoyl)-butyric acid ethyl ester (2) (Step A of Scheme 1)

In a 500 mL flask equipped with a septum and a condenser, 25 g (0.3 mol) ammonium phosphinate and 49 g (0.3 mol) HMDS are heated under N<sub>2</sub> at 110°C for 3.5 h. The reaction mixture is cooled to 5°C where 25 g acrylate 1 in 150 ml dichloromethane is added. The mixture is stirred for 16 h at room temperature. Work-up: 1 N HCl and CH<sub>2</sub>Cl<sub>2</sub> are added. The organic phase is washed with 1 N HCl, the combined acidic phases are re-extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phases are dried over MgSO<sub>4</sub>, evaporated under reduced pressure and dried at 50°C under high vacuum yielding 28.8 g of phosphinic acid 2.

Yield: Quant; M.p.: 152-154°C (white solid); Purity: 89 % (<sup>31</sup>P-NMR)

<sup>31</sup>P-NMR (CDCl<sub>3</sub>, 400MHz): 32.0 ppm (s).

MS (ESI neg.): 957 [2M – H], 478 [M – H].

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400MHz) : 1.2 (t, 3H), 1.8 (m, 1H), 1.9 (2H), 2.05 (m, 1H), 2.25 (m, 1H), 2.7 (m, 1H), 4.1 (q, 2H), 6.3 - 7.7 (d, 1H, P-H, J = 560 Hz), 6.9 (s, 1H, NH), 7.2 (15H, trityl-H), 8.2 (1H, P-OH).

$^{13}\text{C}$ -NMR ( $\text{CDCl}_3$ , 400MHz): 14.2 ( $\text{CH}_3$ ), 28.7 (d,  $\text{CH}_2$ ), 30.8, 31.8 (d, P- $\text{CH}_2$ ), 34.3 (s,  $\text{CH}_2$ ), 38.2 ( $\text{CH}$ ), 61.2 ( $\text{OCH}_2$ ), 70.5 ( $\text{Ph}_3\text{C}$ ), 127.0 (3C, Trityl- $\text{CH}$ ), 127.9 (6C, Trityl- $\text{CH}$ ), 128.7 (6C, Trityl- $\text{CH}$ ), 144.6 (3C, Trityl-C), 171.0 ( $\text{C}=\text{O}$ ), 174.0 ( $\text{C}=\text{O}$ ).

B) Preparation of 2-[Hydroxy-(1,1,3,3-tetramethyl-indan-5-yl)methyl]-phosphinoyl-methyl]-4-(trityl-carbamoyl)-butyric acid ethyl ester (4l) (Step B of Scheme 1)

In a 100 mL flask equipped with a septum and a condenser, monoalkylphosphinic acid 2 (3 g, 6.4 mmol) is dissolved in dry  $\text{CH}_2\text{Cl}_2$  (20 ml). 5-Bromomethyl-1,1,3,3-tetramethyl-indan 6l (1.9 g, 7 mmol) and BSA (3.9 g, 19 mmol) are added and the mixture is stirred 72 h at 25°C. Work-up: The mixture is poured on 1N HCl. The organic phase is washed with 1N HCl, the combined acidic phases are re-extracted with 1N HCl. The combined organic phases are dried over  $\text{MgSO}_4$ , evaporated under reduced pressure and dried at 50°C under high vacuum to give 4.77 g of the bisalkylated phosphinic acid 4l.

Yield: Quant; Purity: 82 % ( $^{31}\text{P}$ -NMR)

$^{31}\text{P}$ -NMR ( $\text{CDCl}_3$ , 400MHz): 53.8 ppm (s).

MS (ESI neg.): 1329 (10% [ $2\text{M} - \text{H}$ ]), 664 (100% [ $\text{M} - \text{H}$ ]), 494 (30%).

$^1\text{H}$ -NMR ( $\text{CDCl}_3$ , 400MHz) : 1.2 (t, 3H), 1.3 (14H), 1.7 (m, 1H), 1.9 (d, 2H, P- $\text{CH}_2$ ), 2.1 (m, 1H), 2.25 (2H), 2.7 (m, 1H), 3.0 (d, 2H, P- $\text{CH}_2$ ), 4.1 (q, 2H,  $\text{OCH}_2$ ), 6.85 (s, 1H, NH), 7.2 (15H, trityl-H), 8.4 (s, 1H, P-OH).

Whereas this synthesis is described with reference to the "R" residue relating to compound 4l above, this synthesis is carried out for the preparation of other benzylic, or allylic phosphinoyl compounds whose "R" residues correspond to the compounds 4d, 4e, 4g, 4h, 4i, 4k, 4m, 4n, 4o, 4p, 4q, 4r, 4s, 4zd, 4ze and 4zf.

The 3 eq BSA of the above procedure can be replaced by 5-7 eq HMDS and the work-up can be simplified by addition of ethanol followed by concentration. In this way 4e, 4f and 4n were prepared.

C) Preparation of 4-Carbamoyl-2-[hydroxy-(4,4,4-trifluoro-butyl)-phosphinoylmethyl]-butyric acid (4b): (Step C of Scheme 1)

0.3 g (1.7 mmol) (4,4,4-trifluoro-butyl)-phosphinic acid 3b (0.3 g, 1.7 mmol) is dissolved in HMDS (1.4 g, 8.5 mmol) at room temperature and heated at 130°C for 4 h. At 80°C acrylate 1 (0.7 g, 1.7 mmol) is added and the reaction mixture heated at 130°C for 16 h. Ethanol is added at 60°C and the mixture refluxed for 30 min. The solvents are removed under reduced pressure and the residue is dried at 50°C under high vacuum for 8 h to yield 0.9 g of 4b.

Yield: 89 %; Purity: ~80 % (<sup>1</sup>H-NMR)

<sup>31</sup>P-NMR (CDCl<sub>3</sub>, 400MHz): 45.3 ppm (s).

MS (ESI neg.): 670 (8% [M + NaOAc - H], 588 (100% [M - H]).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400MHz) : 1.2 (t, 3H), 1.55 (m, 2H), 1.7 (m, 1H), 1.8 (3H), 1.95 (m, 1H), 2.15 (3H), 2.2 (m, 1H), 2.4 (m, 1H), 2.75 (m, 1H), 4.1 (q, 2H), 6.8 (s, 1H, NH), 7.2 (Trityl-H).

Whereas this synthesis is described with reference to the "R" residue relating to compound 4b (above), this synthesis is carried out for the preparation of other phosphinoyl compounds whose "R" residues correspond to the compounds 4a, 4c, 4f, 4i, 4t, 4u, 4v, 4w, 4x, 4y, 4z, 4za to 4zc and 4zg.

Example 2: Preparation of 4-Carbamoyl-2-[(3,7-dimethyl-octyl)-hydroxy-phosphinoyl-methyl]-butyric acid (5n) (Steps D,E ,F of Scheme 1):

Step D: 288 g (0.4 mol) of the P-geranyl phosphinoyl compound 4n (prepared according to Example 1B) is dissolved in 1.4L ethanol at 70°C. 58 g of platinum (2.5% on charcoal / H<sub>2</sub>O 1:1) is added at room temperature and the mixture is stirred under hydrogen for several days until complete hydrogenation (of the 2 double bonds) is detected by <sup>1</sup>H-NMR or MS / ESI. The mixture is filtered over Celite which is washed with 0.3L ethanol.

Step E: 2L LiOH (1N in H<sub>2</sub>O) are added to the filtrate. Under stirring the solution is heated to 50°C for 1-2 days until complete hydrolysis is detected by <sup>1</sup>H-NMR or MS / ESI. The solution is neutralized by addition of ca. 250 ml conc. HCl. The supernatant solution is decanted from the precipitates, the ethanol is removed from this solution

under reduced pressure and the remaining H<sub>2</sub>O phase is extracted with 3 x 0.5L CH<sub>2</sub>Cl<sub>2</sub>. The above precipitates are dissolved in 1.5L CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers are dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure to give 206 g of a reddish solid.

Step F: The resulting material of Step E (ca. 0.35 mol) is dissolved in 2.5L trifluoroacetic acid. 120 g (0.75 mol) triisopropylsilane is added and the resulting suspension stirred for 4 h at room temperature. The trifluoroacetic acid is removed under reduced pressure. 3L H<sub>2</sub>O is added to the residue and the resulting suspension stirred at 60°C for 15 min. The supernatant water-phase is decanted off. 3L NH<sub>3</sub> (6% in water) is added to the residue, the resulting suspension is stirred at 60°C for 15 min and filtered over Celite. The filtrate is divided into 3 portions and filtered over 3 Chromabond C18-columns filled each with 10 g RP (Reverse Phase) material. The filtrates are concentrated under reduced pressure. To the residues toluene is added and removed under reduced pressure (3 times). Drying under high vacuum gives 109 g of a white-yellow solid foam.

Yield: 78% (based on substrate 4n); Purity: 90 % (<sup>31</sup>P-NMR)

<sup>31</sup>P-NMR (D<sub>2</sub>O, 400MHz): 44.8 ppm (s).

MS (ESI neg.): 348 (100% [M – H]).

<sup>1</sup>H-NMR (D<sub>2</sub>O, 400MHz) : 1.2 (2d, 9H), 1.0-1.7 (13H), 1.8-2.0 (3H), 2.2-2.3 (t, 2H, P-CH<sub>2</sub>), 2.5-2.6 (1H), 4.8 (4H, CO<sub>2</sub>H, POH, NH<sub>2</sub>) ppm.

<sup>13</sup>C-NMR (D<sub>2</sub>O, 400MHz): 18.7, 18.8, 22.4, 22.5, 24.6 (CH<sub>2</sub>), 27.7, 27.2 and 28 (d, P-CH<sub>2</sub>), 29.3 (CH<sub>2</sub>), 30.7 and 31.7 (d, P-CH<sub>2</sub>), 32.8 (CH<sub>2</sub>), 33.7, 33.8, 36.5 (CH<sub>2</sub>), 39.1 (CH<sub>2</sub>), 40.0, 178.2 (C=O), 179.6 (C=O).

Whereas this synthesis is described with reference to the "R" residue relating to compound 5n (above), this synthesis is carried out for the preparation of other phosphinoyl compounds whose "R" residues correspond to the compounds 5zc, 5zd, 5ze and 5zf which are derived from P-alkyl-, and P-γ,γ-disubstituted allyl-phosphinoyl compounds 4zc, 4zd, 4ze, and 4zf which are prone to oxaphospholane formation under acidic conditions. Therefore the corresponding C=C-double bonds were removed by hydrogenation, prior to hydrolysis / detritylation.



All other phosphinoyl compounds (5a – 5m, 5o to 5zb and 5zg) were prepared without prior hydrogenation (Step D) just by hydrolysis / detritylation (Steps E and F).

Compound 5zc was also prepared following the general procedure of Example 2 except that the hydrogenation was carried out over Raney-Nickel in place of platinum on charcoal (Step D).

Example 3: Preparation of 7-Bromomethyl-1,1,2,4,4-pentamethyl-1,2,3,4-tetrahydro-naphthalene 6i: (Step G of Scheme 2)

In a 100mL flask equipped with thermometer, septum and a condenser 21.6 g (0.1 mol) 1,1,2,4,4,7-hexamethyl-1,2,3,4-tetrahydro-naphthalene (prepared as described by Wood, T. F.; Easter, W. M., Jr.; Carpenter, M. S.; Angiolini, J. Org. Chem.28, 2248 (1963)) is heated to 170°C. 16 g (0.1 mol) Bromine is added and the reaction mixture stirred for 5 h at 170°C. The content of the flask is fractionated over a Vigreux column (110°C, 4 mbar) giving 17 g (58%) 6i as a colorless liquid.

Yield: 58%; GC-purity: 71%

GC/MS: 294 / 296 (5%,  $[M]^+$ ), 279 / 281 (10%,  $[M - CH_3]^+$ ), 215 (100%,  $[M - Br]^+$ , 201 (65%,  $[M - CH_2Br]^+$ ), 157 (55%).

$^1H$ -NMR ( $CDCl_3$ , 400MHz) : 0.95 (d, 3H), 1.05 (s, 3H), 1.25 (s, 3H), 1.3 (s, 3H), 1.35 (s, 3H), 1.4 (dd, 1H, A), 1.65 (dd, 1H, B), 1.85 (m, 1H, CH), 4.5 (s, 2H,  $CH_2Br$ ), 7.15 (d, 1H, Ar-H), 7.25 (d, 1H, Ar-H), 7.35 (s, 1H, Ar-H).

$^{13}C$ -NMR ( $CDCl_3$ , 400MHz): 16.8 ( $CH_3$ ), 25.0 ( $CH_3$ ), 28.5 ( $CH_3$ ), 31.9 ( $CH_3$ ), 32.3 ( $CH_3$ ), 34.3 ( $CH_2$ ), 34.4 (C), 34.5 (CH), 37.8 (C), 43.5 ( $CH_2Br$ ), 126.2, 127.0, 127.7 (Ar-CH), 134.7, 145.2, 146.5 (Ar-C).

Example 4: Preparation of (5-Iodo-3-methyl-pentyl)-benzene 7c: (Step H of Scheme 2)  
5 g (28 mmol) Phenoxanol (3-Methyl-5-phenyl-pentan-1-ol) is dissolved in 200 ml dichloromethane under nitrogen and stirring. Triphenylphosphine (8.8 g, 34 mmol) and 4.2 g (53 mmol) pyridine are added at 25°C. After cooling to 0°C iodine (8.5 g, 34 mmol) is added. After 2 h stirring at 0°C the reaction mixture is poured on ice-cooled 1 N HCl and extracted with dichloromethane. The combined organic phases are washed

with 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, sat. NaHCO<sub>3</sub> and sat. NaCl. Drying over MgSO<sub>4</sub> and evaporation gives 17g of a residue which is triturated with hexane and filtered over a 5 cm Silicagel pad. The filtrate is evaporated under reduced pressure and dried under high vacuum giving 7.1 g of 7c as a colorless oil.

Yield: 88%; Purity: > 95% (GC, NMR)

GC/MS: 288 (5%, [M]<sup>+</sup>), 161 (10%, [M - I]<sup>+</sup>),

119 (5%), 105 (20%, [PhCH<sub>2</sub>CH<sub>2</sub>]<sup>+</sup>), 91(100%, [[PhCH<sub>2</sub>]<sup>+</sup>).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400MHz) : 0.95 (d, 3H, CH<sub>3</sub>), 1.45 (m, 1H), 1.6 (3H), 1.9 (m, 1H), 2.6 (2H, PhCH<sub>2</sub>), 3.2 (2H, CH<sub>2</sub>I), 7.2 (5H, ArH).

<sup>13</sup>C-NMR (CDCl<sub>3</sub>, 400MHz): 4.9 (CH<sub>2</sub>), 18.7 (CH<sub>3</sub>), 33.3 (CH<sub>2</sub>), 33.7 (CH<sub>3</sub>), 38.2 (CH<sub>2</sub>), 40.9 (CH<sub>2</sub>), 125.8, 128.3, 128.4 (ArCH), 142.5 (ArC).

Example 4: Preparation of E-1-(3-Bromo-2-methyl-propenyl)-4-tert-butyl-benzene 8o:  
(Steps I and J of Scheme 2)

20 g (0.1 mol) E-3-(4-tert-Butyl-phenyl)-2-methyl-propenal (prepared according to US 4435585) is added to a stirred solution of 1.2 g (32 mmol) of sodium borohydride in 20 ml of methanol at 0°C. After 2 h at room temperature quantitative conversion is checked by TLC. The reaction mixture is poured onto 40 ml saturated sodium chloride and extracted with tert-butyl methyl ether. Drying over magnesium sulfate and evaporation of the solvent gives the crude allylic alcohol (19.2 g, 94%), which is transferred to the following bromination reaction without further purification.

5 g (24 mmol) of the crude allylic alcohol is dissolved in 35 ml of dry diethyl ether under nitrogen. At 0°C phosphorus tribromide (0.95 ml, 10 mmol) is added via syringe. The reaction is stirred at 0°C for 4 h, poured onto ice and extracted three times with diethyl ether. The organic layer is washed with saturated NaHCO<sub>3</sub> and dried over MgSO<sub>4</sub>. The solvent is removed under reduced pressure giving the crude allylic bromide 5.7 g of 8o.

Yield: 5.7 g (87% from the aldehyde); Purity: > 95% (GC, NMR)

GC/MS: 266 / 268 (3%, [M]<sup>+</sup>), 251 (1%, [M - CH<sub>3</sub>]<sup>+</sup>), 188 (25%, [M - Br]<sup>+</sup>), 173 (55%, [M - Br - CH<sub>3</sub>]<sup>+</sup>), 157 (10%), 131 (55%), 115 (22%), 91 (16%), 57 (100%).

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400MHz): 1.3 (s, 9H, tBu- $\text{CH}_3$ ), 2.0 (s, 3H,  $\text{CH}_3$ ), 4.15 (s, 2H,  $\text{CH}_2\text{Br}$ ), 6.6 (s, 1H,  $=\text{CH}$ ), 7.22 (d, 2H, Ar-H), 7.35 (s, 2H, Ar-H).

$^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ , 400MHz): 16.6 ( $\text{CH}_3$ ), 31.3 (3C, tBu- $\text{CH}_3$ ), 34.6 (tBu-C), 42.6 ( $\text{CH}_2$ ), 125.2, 128.7 (ArCH), 130.0 ( $=\text{CH}$ ), 133.7, 134.0 (Ar-C), 150.2 ( $=\text{C}$ )

Example 6: Preparation of (3,7-Dimethyl-octa-2,6-dienyl)-phosphinic acid 3n: (Step K of Scheme 2)

In a 750mL flask equipped with septum, thermometer and condenser, ammonium phosphinate (25 g, 0.3 mol) and HMDS (51 g, 0.32 mmol) are heated under  $\text{N}_2$  at  $110^\circ\text{C}$  for 3 h. The reaction mixture is cooled to  $0^\circ\text{C}$ . 300 mL dried  $\text{CH}_2\text{Cl}_2$  are added followed by the addition of geranyl bromide (13.1 g, 60 mmol). The mixture is stirred for 16 h at room temperature. 10 ml methanol are added and the fine suspension is filtered over a double filter layer. The filtrate is concentrated under reduced pressure. 10%  $\text{Na}_2\text{CO}_3$  and *tert*-butyl methyl ether are added, the phases are separated and the alkaline layer purified with *tert*-butyl methyl ether. The alkaline layer is treated with conc. HCl until pH = 1 and is then 3 times extracted with dichloromethane. Drying of the dichloromethane layer over  $\text{MgSO}_4$  and evaporation give 13.7 g (81%) of 3n as orange oil.

Yield: 13.7 g (81%); Purity: 77% ( $^{31}\text{P-NMR}$ )

$^{31}\text{P-NMR}$  ( $\text{CDCl}_3$ , 400MHz): 34.9 ppm (s).

MS (ESI neg.): 403 (10%  $[2\text{M} - \text{H}]^+$ ), 201 (100%,  $[\text{M} - \text{H}]^+$ ).

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400MHz): 1.2 (d, 1H), 1.6 (s, 3H,  $\text{CH}_3$ ), 1.6 (6H, 2  $\text{CH}_3$ ), 2.1 (4H,  $\text{CH}_2\text{CH}_2$ ), 2.6 (dd, 2H, P- $\text{CH}_2$ ), 5.1 (1H,  $=\text{CH}$ ), 5.15 (1H,  $=\text{CH}$ ), 6.22 and 7.6 (d, 1H, J = 548 Hz, P-H), 11.8 (s, 1H, POH).

$^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ , 400MHz): 16.5 ( $\text{CH}_3$ ), 17.6 ( $\text{CH}_3$ ), 25.6 ( $\text{CH}_3$ ), 26.4 ( $\text{CH}_2$ ), 30.4 and 29.5 (d, P- $\text{CH}_2$ ), 39.7 ( $\text{CH}_2$ ), 110.5 ( $=\text{CH}$ ), 123.7 ( $=\text{CH}$ ), 131.7 ( $=\text{C}$ ), 141.9 ( $=\text{C}$ ).

Example 7: Preparation of (3-phenyl-propyl)-phosphinic acid 3t: (Step L of Scheme 2)

To a solution of  $\text{NaH}_2\text{PO}_2(\text{H}_2\text{O})$  (13.2 g, 0.125 mol) and allylbenzene (6.6 g, 56 mmol) in methanol (250 ml) is added triethylborane (1M in THF, 50 ml, 50 mmol) at room

temperature in an open 500 ml flask. The solution is stirred for 2 h at room temperature. The reaction mixture is concentrated under reduced pressure. 100 ml saturated  $\text{KHSO}_4$  are added to the residue followed by extraction (200, 100 and 70 ml) with ethyl acetate. To the combined ethyl acetate layers are added 40 ml 10%  $\text{Na}_2\text{CO}_3$ . Under vigorous stirring and dropwise addition of conc.  $\text{NaOH}$  the biphasic mixture is adjusted to  $\text{pH} = 10$ . The organic phase is separated and the alkaline phase adjusted to  $\text{pH} = 2$  by addition of conc.  $\text{HCl}$ . Extraction with chloroform (3 x 100 ml), drying of the combined organic layer over  $\text{MgSO}_4$  and evaporation gives 5.4 g of crude 3t (61%).

Yield: 61%; Purity: 84% ( $^{31}\text{P}$ -NMR)

$^{31}\text{P}$ -NMR ( $\text{CDCl}_3$ , 400MHz): 38.2 ppm (s).

MS (ESI neg.): 265 (6%  $[\text{M} - \text{H} + \text{NaOAc}]^+$ ), 183 (100%,  $[\text{M} - \text{H}]^+$ ).

$^1\text{H}$ -NMR ( $\text{CDCl}_3$ , 400MHz): 1.75 (m, 2H,  $\text{CH}_2$ ), 1.9 (m, 2H,  $\text{CH}_2$ ), 2.76 (t, 2H,  $\text{PhCH}_2$ ), 6.4 and 7.7 (d, 1H,  $J = 548 \text{ Hz}$ , P-H), 11.4 (s, 1H, POH).

#### Example 8: Measuring inhibitory activity

Cellular Extracts of *Corynebacterium striatum* Ax 20 (DSM 14267) are prepared by mechanical disruption and subsequent centrifugation.

The extract (50  $\mu\text{l}$  ml corresponding to 0.2 ml initial cell culture) is added to 50  $\mu\text{l}$  of Buffer A (Phosphate Buffer,  $\text{pH} 7$ ). Various concentrations of the compounds of the present invention are added in a volume of 40  $\mu\text{l}$ , and after 10 min preincubation at  $37^\circ\text{C}$ , the reaction is amended with 10  $\mu\text{l}$  of substrate (N $\alpha$ -lauroyl-L-glutamine, final concentration 50  $\mu\text{M}$ ). The samples are incubated for 15 min and then the reaction is stopped by adding 75  $\mu\text{l}$  of Fluorescamine (2.5 mM dissolved in Acetonitrile). The fluorescence resulting from derivatization of the released glutamine with fluorescamine is determined at an excitation wavelength of 381 nm and an emission wavelength of 470 nm. By comparing the samples containing compounds of the present invention with control samples with enzyme and substrate only, the inhibition (%) is calculated. Alternatively, the same assay is made with a recombinantly formed enzyme produced with a strain containing an expression vector comprising a nucleic acid sequence

encoding for the enzyme. The results for some compounds of the present invention are listed in Table 1.

**Table 1. Enzyme inhibition**

Compound	IC <sub>50</sub> value (nM)	Compound	IC <sub>50</sub> value (nM)
5a	30.3	5x	40
5c	11.5	5z	32
5g	137.5	5y	17.9
5t	125	5n	9

In order to evaluate enzyme activity in intact cells, stationary phase living cells of Ax20 are harvested and resuspended in Buffer A to an optical density at 600 nm of 0.25.

Inhibitory compounds are added at various concentrations, and after a preincubation of 15 min, the substrate (N $\alpha$ -lauroyl-L-glutamine, 1 mM final concentration) is added. The samples are incubated for 1 h and then extracted with MTBE and HCl and analysed for released lauric acid using capillary GC. By comparing the samples containing compounds of the present invention with control samples with bacteria and substrate only, the inhibition (%) is calculated. By comparing the inhibitory capacity of the compounds on the isolated enzyme with the values obtained using intact cells, the relative uptake of the compounds by the cells can be assessed. From Table 2 it appears, that compounds of the present invention can cross the bacterial cell wall and cytoplasmatic membrane, and thus can have inhibitory activity in living cells.


**Table 2. Inhibition of the enzymatic activity in living cells at the concentration of 0.2 micromolar**

Compound	% inhibition of release of fatty acids by <i>Corynebacterium</i> Ax20 at a concentration of 0.2 $\mu$ M
5a	60.9
5c	70.5
5n	69.5
5y	64.9

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

Givaudan SA  
1214 Vernier  
SwitzerlandRECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR:  Ax 20	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 14267
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by:  <input checked="" type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation  (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2001-04-26 (Date of the original deposit) <sup>1</sup> .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):    Date: 2001-04-30

<sup>1</sup> Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

Sequence listing part of description

## SEQUENCE LISTING

<110> Givaudan SA  
 <120> Organic compounds  
 <130> 30076 PCT  
 <150> GB 0226550.2  
 <151> 2002-11-14  
 <160> 2  
 <170> PatentIn version 3.1  
  
 <210> 1  
 <211> 399  
 <212> PRT  
 <213> Corynebacterium striatum

<400> 1

Ala	Gln	Glu	Asn	Leu	Gln	Lys	Ile	Val	Asp	Ser	Leu	Glu	Ser	Ser	Arg	1	5	10	15
Ala	Glu	Arg	Glu	Glu	Leu	Tyr	Lys	Trp	Phe	His	Gln	His	Pro	Glu	Met	20	25	30	
Ser	Met	Gln	Glu	His	Glu	Thr	Ser	Lys	Arg	Ile	Ala	Glu	Glu	Leu	Glu	35	40	45	
Lys	Leu	Gly	Leu	Glu	Pro	Gln	Asn	Ile	Gly	Val	Thr	Gly	Gln	Val	Ala	50	55	60	
Val	Ile	Lys	Asn	Gly	Glu	Gly	Pro	Ser	Val	Ala	Phe	Arg	Ala	Asp	Phe	65	70	75	80
Asp	Ala	Leu	Pro	Ile	Thr	Glu	Asn	Thr	Gly	Leu	Asp	Tyr	Ser	Ala	Asp	85	90	95	
Pro	Glu	Leu	Gly	Met	Met	His	Ala	Cys	Gly	His	Asp	Leu	His	Thr	Thr	100	105	110	
Ala	Leu	Leu	Gly	Ala	Val	Arg	Ala	Leu	Val	Glu	Asn	Lys	Asp	Leu	Trp	115	120	125	
Ser	Gly	Thr	Phe	Ile	Ala	Val	His	Gln	Pro	Gly	Glu	Glu	Gly	Gly	Gly	130	135	140	
Gly	Ala	Arg	His	Met	Val	Asp	Asp	Gly	Leu	Ala	Glu	Lys	Ile	Ala	Ala	145	150	155	160
Pro	Asp	Val	Cys	Phe	Ala	Gln	His	Val	Phe	Asn	Glu	Asp	Pro	Ala	Phe	165	170	175	
Gly	Tyr	Val	Phe	Thr	Pro	Gly	Arg	Phe	Leu	Thr	Ala	Ala	Ser	Asn	Trp	180	185	190	
Arg	Ile	His	Ile	His	Gly	Glu	Gly	Gly	His	Gly	Ser	Arg	Pro	His	Leu				

23

195	200	205
Thr Lys Asp Pro Ile Val Val Ala Ala Ser Ile Ile Thr Lys Leu Gln 210 215 220		
Thr Ile Val Ser Arg Glu Val Asp Pro Asn Glu Val Ala Val Val Thr 225 230 235 240		
Val Gly Ser Ile Glu Gly Gly Lys Ser Thr Asn Ser Ile Pro Tyr Thr 245 250 255		
Val Thr Leu Gly Val Asn Thr Arg Ala Ser Asn Asp Glu Leu Ser Glu 260 265 270		
Tyr Val Gln Asn Ala Ile Lys Arg Ile Val Ile Ala Glu Cys Gln Ala 275 280 285		
Ala Gly Ile Glu Gln Glu Pro Glu Phe Glu Tyr Leu Asp Ser Val Pro 290 295 300		
Ala Val Ile Asn Asp Glu Asp Leu Thr Glu Gln Leu Met Ala Gln Phe 305 310 315 320		
Arg Glu Phe Phe Gly Glu Asp Gln Ala Val Glu Ile Pro Pro Leu Ser 325 330 335		
Gly Ser Glu Asp Tyr Pro Phe Ile Pro Asn Ala Trp Gly Val Pro Ser 340 345 350		
Val Met Trp Gly Trp Ser Gly Phe Ala Ala Gly Ser Asp Ala Pro Gly 355 360 365		
Asn His Thr Asp Lys Phe Ala Pro Glu Leu Pro Asp Ala Leu Glu Arg 370 375 380		
Gly Thr Gln Ala Ile Leu Val Ala Ala Ala Pro Trp Leu Met Lys 385 390 395		

&lt;210&gt; 2

&lt;211&gt; 1212

&lt;212&gt; DNA

&lt;213&gt; Corynebacterium striatum

&lt;400&gt; 2

```

aatcgggtca tggcacagga aaatttgcaa aagattgtag atagtctcga gtcctcccgc   60
gcggaacgcg aagaactgta caagtgggtc caccagcacc cggaaatgtc gatgcaggag  120
cacgaaacct ccaagcgcac cgcagaagag ctagagaagc tcggccttga gccgcagaac  180
atcggcgtga ccgggcaggt cgcggtaatc aagaacggtg aaggcccgag cgtggcattt  240
cgtgcggact ttgatgcctt gccgatcacc gagaacaccg ggctggatta ctcggcggat  300
cccgagctgg gcatgatgca cgctgcggc caccgatttg acaccactgc cctactcggc  360
gcggtgcgcg cgctggtgga gaacaaggac ctgtggtccg gcaccttcat cgcagtccac  420


```



caaccocggtg aggaaggcgg cggcggggcc cgccacatgg tggacgacgg cctcgcggag 480  
aagatocgcg cgccggatgt gtgtttcgcc cagcacgtgt tcaacgaaga ccccgcccttt 540  
ggctacgtgt tcacccccgg ccggtttcta acggcggcgt cgaactggag aatccacatc 600  
cacggcgagg gcggacacgg ttcccggtccg cacctgacca aggaccgat tgtggtggcg 660  
gcctcgatca ttaccaagct gcagacgatt gtctcccgcg aagtcgatcc gaatgaggtc 720  
gcagtgggtca ccgtcggctc catcgagggc ggcaagtcca ccaactcgat cccgtacacc 780  
gtcacccctcg gcgtgaacac ccgagcctcc aacgatgagc tctccgagta cgtccagaac 840  
gccatcaagc gcacgtcat cgcggagtgc caggctgcag gcacgaaca ggagccggaa 900  
ttcgagtacc tggactcagt cccggccgtg atcaacgacg aggatctcac cgaacagctc 960  
atggcgaggt tccgggagtt ctccggcgag gaccaggcgg tagagattcc gcccctgtcc 1020  
ggcagcgagg actaccctt cattccgaac gcctggggcg tgccgagtgt gatgtgggga 1080  
tggtccggct tcgccgagg ttctgacgca ccgggcaatc acaccgacaa gtccgcccc 1140  
gagcttccag atgccctcga acgcggcacc caggccattc tgggtggccgc cgcgccctgg 1200  
ttgatgaagt ga 1212

## Claims

1. A compound of formula (I)



wherein R is a substituted alkyl, benzyl or allyl residue selected from the group consisting of nonyl; 4,4,4-trifluoro-propyl; 2-methyl-4-phenyl-butyl; 4-trifluoromethyl-phenyl; pentafluorophenyl; 4-fluoro-phenyl; naphthalene-2-yl; biphenyl-2-yl; 5,5,7,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalene-2-yl; 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl; 1,1,3,3-tetramethyl-indan-5-yl; styryl; 2,6-dimethyl-heptyl; 2-(4-tert-Butyl-phenyl)-1-methyl-vinyl; 2-(4-Isopropyl-phenyl)-1-methyl-vinyl; 1-(1,7,7-Trimethyl-bicyclo[2.2.1]hept-2-yl)-ethyl; 2-(4-Isobutyl-phenyl)-1-methyl-vinyl; 2-(2-isopropyl-phenyl)-1-methyl-ethenyl; 2-phenyl-ethyl; cyclohexyl-methyl; 2,2-dimethyl-propyl; 2-(pentafluorophenyl)-ethyl; 3-phenyl-propyl; heptyl; 4-isopropyl-cyclohex-1-enyl; decyl; hexyl; trans-4-isopropyl-cyclohexyl; 5-ethyl-2-methyl-heptyl; 2,6,10-trimethyl-undecyl; 1-methyl-3-(2,2,3-trimethyl-cyclopentyl)-propyl; and octyl.

2. A composition comprising a body odour-suppressing quantity of a compound claimed in claim 1.
3. Composition according to claim 2 wherein the compound is present in amounts of about 0.01 to 0.5 % by weight.
4. Composition according to claim 2 or claim 3 selected from cosmetic and personal care products, in particular deo-sticks, roll-ons, pump-sprays, aerosols, deodorant soaps, powders, solutions, gels, creams, sticks, balms and lotions.

5. Use of a compound as defined in claim 1 or composition comprising a compound as defined in claim 1 to inhibit an enzyme in its ability to cleave compounds contained in sweat into short-chained, branched fatty acids, which enzyme is produced in bacteria of the genus *Corynebacteria*, which bacteria has been deposited at the International Depository Authority DSMZ- Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, D-38124 Braunschweig under the Accession Number DSM 14267.
6. Use of a compound as defined in claim 1 or composition comprising a compound as defined in claim 1 to inhibit an enzyme in its ability to cleave compounds contained in sweat into short-chained, branched fatty acids, which enzyme is defined by an amino acid sequence set forth as SEQ ID No. 1.
7. A method of suppressing axillary malodour comprising the step of providing a composition for application to the skin of a person in need of treatment, said composition containing an inhibitor compound and a dermatologically acceptable vehicle therefore, said compound being selected from one or more compounds as defined by claim 1.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH 03/00750

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07F9/30

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 02/092024 A (ACUNA GONZALO ; GIVAUDAN SA (CH); GFELLER HANS (CH); NATSCH ANDREAS (C) 21 November 2002 (2002-11-21) cited in the application page 10; claims 11-13, 16-18; figure 2	1-4, 7
A	EP 0 265 412 A (MONSANTO CO) 27 April 1988 (1988-04-27) page 2, line 8 - line 26	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

16 February 2004

Date of mailing of the international search report

10/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Richter, H

Information on patent family members

International Application No

PCT/CH 03/00750

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 02092024	A	21-11-2002	EP	1258531 A1		20-11-2002
			WO	02092024 A2		21-11-2002
			EP	1387891 A2		11-02-2004
EP 0265412	A	27-04-1988	AT	73457 T		15-03-1992
			DE	3777325 D1		16-04-1992
			EP	0265412 A2		27-04-1988
			JP	63122694 A		26-05-1988
			US	4764620 A		16-08-1988